Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16338234 | 0.76 | MELK (0.42) | MELKALDH1A1NPSR1L3MBTL1 | |
| SCHEMBL14905211 | 0.75 | EGFR (0.38) | MELKKDM4ETDP1ADRA2AADRA2B | |
| SCHEMBL29810194 | 0.74 | MELK (0.42) | MELKKDM4EALDH1A1MAPTTDP1 | |
| SCHEMBL12663631 | 0.73 | KDM4E (0.50) | KDM4ENPC1ALDH1A1MAPTXBP1 | |
| SCHEMBL15130437 | 0.73 | MELK (0.49) | MELK | |
| SCHEMBL796948 | 0.72 | MAPT (0.43) | KDM4EALDH1A1MAPTTDP1L3MBTL1 | |
| SCHEMBL24569776 | 0.71 | CSNK1A1 (0.38) | MELKALDH1A1NPSR1TDP1EGFR | |
| SCHEMBL30083629 | 0.71 | CSNK1A1 (0.38) | MELKALDH1A1NPSR1TDP1EGFR | |
| SCHEMBL15130350 | 0.69 | MELK (0.45) | MELK | |
| SCHEMBL6286366 | 0.67 | DYRK1A (0.50) | MELKKDM4ENPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181264-B2 | Fused heteroaryls and their uses | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-11-10 | — | — | US | disclosed |
| US-9181264-B2 | Fused heteroaryls and their uses | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-11-10 | — | — | US | disclosed |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-25 | — | — | US | disclosed |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-25 | — | — | US | disclosed |
| WO-2012034526-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | FARS2, TIAL1, DHFR | MELK 2540/4885KDM4E 4268/4885NPC1 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.